HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane.

Abstract
The synthesis, physical properties, and antitumor activity of the cis-, d,l-trans-, d-trans-, and l-trans- stereoisomers of 1,2-diaminocyclohexane tetrachloroplatinum(IV) are described. The objective of the study was to produce a platinum complex with activity against cisplatin-resistant tumor cells and with suitable pharmaceutical properties for formulation development. The isomers had the following solubilities in saline: cis-, 2 mg/ml; d,l-trans-, 6.5 mg/ml; and d-trans- and l-trans-, 15-16 mg/ml. The four complexes showed slightly better activity than cisplatin against the ip implanted murine L1210 leukemia. In contrast to cisplatin, all complexes produced significant increases in life span against L1210/cisplatin, a subline of L1210 with acquired resistance to cisplatin. However, the cis- isomer was less active against L1210/cisplatin. The d,l-trans- isomer (tetraplatin) was selected for further studies based on greater ease for large-scale synthesis. It showed superior activity to cisplatin against P388/cisplatin and like cisplatin showed significant and reproducible activity against the ip implanted B16 melanoma, ip implanted M5076 sarcoma, ip implanted P388 leukemia, and MX-1 human breast xenograft implanted under the renal capsule. Purity and stability (greater than 24 hours in saline) were evaluated by high-performance liquid chromatography and found to be suitable for development of a parenteral dosage form. Preliminary studies in a rat model (to be reported elsewhere) showed it to be less nephrotoxic than cisplatin on a molar basis and worthy of further study.
AuthorsW K Anderson, D A Quagliato, R D Haugwitz, V L Narayanan, M K Wolpert-DeFilippes
JournalCancer treatment reports (Cancer Treat Rep) Vol. 70 Issue 8 Pg. 997-1002 (Aug 1986) ISSN: 0361-5960 [Print] United States
PMID3731155 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Cisplatin
  • ormaplatin
Topics
  • Animals
  • Antineoplastic Agents
  • Body Weight (drug effects)
  • Breast Neoplasms (drug therapy)
  • Cell Line
  • Cisplatin (therapeutic use)
  • Drug Evaluation, Preclinical
  • Drug Resistance
  • Humans
  • Leukemia L1210 (drug therapy, genetics)
  • Leukemia P388 (drug therapy, genetics)
  • Melanoma (drug therapy)
  • Mice
  • Mutation
  • Organoplatinum Compounds (analysis, chemical synthesis, therapeutic use)
  • Rats
  • Sarcoma, Experimental (drug therapy)
  • Stereoisomerism

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: